NexgenRx Inc.
NEGXF · OTC
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Revenue | $3 | $4 | $5 | $4 |
| % Growth | -30.6% | -4.5% | 15.5% | – |
| Cost of Goods Sold | $1 | $1 | $1 | $1 |
| Gross Profit | $2 | $4 | $4 | $3 |
| % Margin | 74.3% | 81.9% | 79.6% | 85.6% |
| R&D Expenses | $0 | $0 | $0 | $0 |
| G&A Expenses | $0 | $0 | $0 | $0 |
| SG&A Expenses | $2 | $0 | $0 | $0 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $3 | $3 | $3 |
| Operating Expenses | $2 | $3 | $3 | $3 |
| Operating Income | $0 | $0 | $1 | $0 |
| % Margin | 4.6% | 7.8% | 12.1% | 11.8% |
| Other Income/Exp. Net | $0 | -$0 | -$0 | -$0 |
| Pre-Tax Income | $0 | $0 | $1 | $0 |
| Tax Expense | -$0 | -$0 | -$0 | $0 |
| Net Income | $0 | $0 | $1 | -$0 |
| % Margin | 14% | 8.1% | 11.6% | -0.7% |
| EPS | 0.006 | 0.005 | 0.007 | -0 |
| % Growth | 12% | -28.6% | 1,850% | – |
| EPS Diluted | 0.006 | 0.005 | 0.006 | -0 |
| Weighted Avg Shares Out | 71 | 71 | 71 | 71 |
| Weighted Avg Shares Out Dil | 71 | 71 | 77 | 74 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $0 | $0 | $0 | $0 |
| EBITDA | $1 | $1 | $1 | $1 |
| % Margin | 22% | 15.2% | 18.2% | 18.9% |